[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO2022000748A2 - Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones - Google Patents

Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones

Info

Publication number
CO2022000748A2
CO2022000748A2 CONC2022/0000748A CO2022000748A CO2022000748A2 CO 2022000748 A2 CO2022000748 A2 CO 2022000748A2 CO 2022000748 A CO2022000748 A CO 2022000748A CO 2022000748 A2 CO2022000748 A2 CO 2022000748A2
Authority
CO
Colombia
Prior art keywords
applications
preparation
method therefor
pyrazolopyrimidine compound
compound
Prior art date
Application number
CONC2022/0000748A
Other languages
English (en)
Inventor
Qian Wang
Sijie Shu
Guangxin Xia
Hui Ge
Bingbin Zhang
Guoyong Huo
Lin Zhang
Chen Shi
Jiangsong Lou
Chi Zhang
Zhihui Zhang
Yu Mao
Jianxin Yu
Ying Ke
Yanjun Liu
Original Assignee
Shanghai Pharmaceuticals Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Pharmaceuticals Holding Co Ltd filed Critical Shanghai Pharmaceuticals Holding Co Ltd
Publication of CO2022000748A2 publication Critical patent/CO2022000748A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/49—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen un compuesto de pirazolopirimidina, un método de preparación para el mismo y aplicaciones del mismo. En la presente invención se proporciona el compuesto de pirazolopirimidina representado por la fórmula (II). El compuesto tiene una actividad inhibidora mejorada con respecto a la quinasa WEE1.
CONC2022/0000748A 2019-06-28 2022-01-27 Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones CO2022000748A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910579671 2019-06-28
PCT/CN2020/098611 WO2020259703A1 (zh) 2019-06-28 2020-06-28 一种吡唑酮并嘧啶类化合物、其制备方法及应用

Publications (1)

Publication Number Publication Date
CO2022000748A2 true CO2022000748A2 (es) 2022-04-29

Family

ID=73888651

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0000748A CO2022000748A2 (es) 2019-06-28 2022-01-27 Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones

Country Status (14)

Country Link
US (1) US20220259210A1 (es)
EP (1) EP3992193A4 (es)
JP (1) JP2022538901A (es)
KR (1) KR20220042127A (es)
CN (1) CN112142747B (es)
AU (1) AU2020306139A1 (es)
BR (1) BR112021026618A2 (es)
CA (1) CA3145344A1 (es)
CL (1) CL2021003517A1 (es)
CO (1) CO2022000748A2 (es)
IL (1) IL289375A (es)
MX (1) MX2021015572A (es)
PH (1) PH12021553263A1 (es)
WO (1) WO2020259703A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591334B (zh) * 2020-12-04 2023-10-20 山东轩竹医药科技有限公司 二氢吡唑并嘧啶酮衍生物
CN115197221B (zh) * 2021-04-02 2024-05-24 轩竹(北京)医药科技有限公司 二氢吡唑并嘧啶酮类大环衍生物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2282673T3 (es) 2002-07-15 2007-10-16 Janssen Pharmaceutica N.V. Analogos 3-furanilo de toxoflavina como inhibidores de quinasas.
GB0420520D0 (en) * 2004-09-15 2004-10-20 Novartis Ag Organic compounds
DE602005024293D1 (de) * 2004-10-21 2010-12-02 Vertex Pharma Triazole als hemmer von proteinkinasen
AU2006205851A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
MX2009010047A (es) 2007-03-20 2009-12-04 Smithkline Beecham Corp Compuestos quimicos.
EA200901138A1 (ru) 2007-03-20 2010-04-30 Смитклайн Бичем Корпорейшн Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
US8507505B2 (en) 2008-12-12 2013-08-13 Msd K.K. Dihydropyrazolopyrimidinone derivative
TW201035100A (en) * 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors
JP2012518598A (ja) 2009-02-25 2012-08-16 Ｍｓｄ株式会社 ピリミドピリミドインダゾール誘導体
TW201105669A (en) * 2009-07-30 2011-02-16 Irm Llc Compounds and compositions as Syk kinase inhibitors
JP6692423B2 (ja) * 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
GB201612092D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
WO2018133829A1 (zh) 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
SG11202000789WA (en) 2017-08-01 2020-02-27 Recurium Ip Holdings Llc 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs
WO2019037678A1 (zh) 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
WO2019096322A1 (zh) * 2017-11-20 2019-05-23 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
US11479555B2 (en) * 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase

Also Published As

Publication number Publication date
BR112021026618A2 (pt) 2022-06-07
PH12021553263A1 (en) 2022-09-12
AU2020306139A1 (en) 2022-02-24
US20220259210A1 (en) 2022-08-18
WO2020259703A1 (zh) 2020-12-30
CL2021003517A1 (es) 2022-08-19
KR20220042127A (ko) 2022-04-04
MX2021015572A (es) 2022-04-06
JP2022538901A (ja) 2022-09-06
CN112142747A (zh) 2020-12-29
CN112142747B (zh) 2024-03-01
CA3145344A1 (en) 2020-12-30
EP3992193A1 (en) 2022-05-04
EP3992193A4 (en) 2023-08-16
IL289375A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
CO2022002637A2 (es) Proceso de fabricación de moduladores de cftr
CL2018001790A1 (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este (divisional solicitud 201602748)
CL2020000594S1 (es) Estuche de auriculares.
MX2018006148A (es) Inhibidores de cxcr2.
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
BR112021017103A2 (pt) Uso de ramnolipídeos
CL2020001201S1 (es) Automóvil.
ECSP19083967A (es) Compuestos antitumorales
MX2020014097A (es) Lipidos novedosos.
CO2022000751A2 (es) Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo
UY36886A (es) Compuesto para usar en composiciones que cambian de color
CL2019002232S1 (es) Automóvil.
CO2022000748A2 (es) Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones
EA202190475A1 (ru) Мини-gde для лечения гликогеноза iii типа
CL2020000217A1 (es) Inhibidores de ror gamma.
BR112018014355A2 (pt) processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
CL2019000050A1 (es) Procesos para la preparacion de oxipicolinamidas 4 - alkoxi - (acil o aquil).
CL2020000174S1 (es) Automóvil.
MX2022000243A (es) Nuevos compuestos heterociclicos.
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
MX2022001608A (es) Sintesis de un inhibidor de calicreina plasmatica a escala de proceso.
CL2022001511A1 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina
MX2020008488A (es) Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo.
BR112018077104A2 (pt) compostos, processo para a preparação de compostos de fórmula i, processo para a preparação de compostos de fórmula iv e uso de compostos da fórmula i
MX2020004034A (es) Metodo de preparacion para un inhibidor de tirosina cinasa e intermediario del mismo.